Protein detail
UFO
Tyrosine-protein kinase receptor UFO (EC 2.7.10.1) (AXL oncogene)
Protein symbol UFO | UniProt ID | EVMP score 0.63 |
Frequency 7 | Transmembrane count 1 | Protein classification Disease related genesEnzymesFDA approved drug targetsPlasma proteinsPredicted membrane proteins |
Basic Information
Protein Names
Tyrosine-protein kinase receptor UFO (EC 2.7.10.1) (AXL oncogene)
Protein Class
Disease related genesEnzymesFDA approved drug targetsPlasma proteinsPredicted membrane proteins
Protein Function
- ENZYME proteins:Transferases
- Enzymes
- Kinases:Tyr protein kinases
- Disease related genes
- FDA approved drug targets:Small molecule drugs
Transmembrane
452..472; Helical
Transmembrane Count
1
Ensembl
Entrez Gene Symbol
Gene Synonym
ARKJTK11Tyro7UFO
Gene Description
AXL receptor tyrosine kinase
Chromosome
19
Position
41219223-41261766
Frequency
7
EVMP Score
0.63
Fluorescence & Localization
Tissue SpecificpancreasCell SpecificAlveolar cells type 1Blood Cell SpecificT-regBlood Lineage Specificdendritic cells
Function & Pathway
Protein Function
- ENZYME proteins:Transferases
- Enzymes
- Kinases:Tyr protein kinases
- Disease related genes
- FDA approved drug targets:Small molecule drugs
Cellular Component
Molecular Function
- GO:0001618 virus receptor activity
- GO:0001786 phosphatidylserine binding
- GO:0004713 protein tyrosine kinase activity
- GO:0004714 transmembrane receptor protein tyrosine kinase activity
- GO:0005515 protein binding
- GO:0005524 ATP binding
- GO:0032036 myosin heavy chain binding
- GO:0043548 phosphatidylinositol 3-kinase binding
Biological Process
Reactome
Mediation Categories
Adhesion and uptake mediationClinical-translation mediationImmune mediationReceptor-signaling mediation
Relations & Evidence
Enzyme-Mediated Modification
7 records.
| Substrate Gene Symbol | Enzyme Gene Symbol | Enzyme UniProt ID | Residue Type | Residue Offset | Modification | Database | References |
|---|---|---|---|---|---|---|---|
| AXL | BMX | P51813 | Y | 821 | phosphorylation | PhosphoNetworks | |
| AXL | HGF | P14210 | Y | 779 | phosphorylation | REACH_ProtMapperSparser_ProtMapperProtMapper | ProtMapper:28675785 |
| AXL | EGFR | P00533 | Y | 779 | phosphorylation | RLIMS-P_ProtMapperSparser_ProtMapperProtMapper | ProtMapper:27775700 |
| AXL | GAS6 | Q14393 | Y | 779 | phosphorylation | Sparser_ProtMapperProtMapper | ProtMapper:27829217 |
| AXL | GAS6 | Q14393 | Y | 702 | phosphorylation | Sparser_ProtMapperProtMapper | ProtMapper:27829217 |
| AXL | SRC | P12931 | Y | 779 | phosphorylation | Sparser_ProtMapperProtMapper | ProtMapper:28675785 |
| AXL | GKN2 | Q86XP6 | Y | 779 | phosphorylation | Sparser_ProtMapperProtMapper | ProtMapper:26313459 |
Ligand-Receptor Signaling
65 records.
| Category | Parent | Database | Transmitter | Receiver | Secreted | Plasma Membrane (Transmembrane) | Plasma Membrane (Peripheral) |
|---|---|---|---|---|---|---|---|
| receptor | receptor | CellPhoneDB | No | Yes | No | Yes | No |
| receptor | receptor | GO_Intercell | No | Yes | No | Yes | No |
| receptor | receptor | HPMR | No | Yes | No | Yes | No |
| receptor | receptor | ICELLNET | No | Yes | No | Yes | No |
| receptor | receptor | CellChatDB | No | Yes | No | Yes | No |
| receptor | receptor | CellTalkDB | No | Yes | No | Yes | No |
| receptor | receptor | Surfaceome | No | Yes | No | Yes | No |
| receptor | receptor | Ramilowski2015 | No | Yes | No | Yes | No |
| receptor | receptor | Guide2Pharma | No | Yes | No | Yes | No |
| receptor | receptor | LRdb | No | Yes | No | Yes | No |
Page 1 of 7Next
Regulatory Interaction Network
13 records.
Page 1 of 2Next
Protein Complex Composition
Isolation & Detection Technology
1 record.
| EV Isolation Method | Detection Method | Number of References | References |
|---|---|---|---|
| Differential Ultracentrifugation | Mass spectrometry | 1 | 37440012 |
Sequence, Structure & Domains
Sequences
Length
894
Mass
98,337
Sequence
MAWRCPRMGRVPLAWCLALCGWACMAPRGTQAEESPFVGNPGNITGARGLTGTLRCQLQVQGEPPEVHWLRDGQILELADSTQTQVPLGEDEQDDWIVVSQLRITSLQLSDTGQYQCLVFLGHQTFVSQPGYVGLEGLPYFLEEPEDRTVAANTPFNLSCQAQGPPEPVDLLWLQDAVPLATAPGHGPQRSLHVPGLNKTSSFSCEAHNAKGVTTSRTATITVLPQQPRNLHLVSRQPTELEVAWTPGLSGIYPLTHCTLQAVLSDDGMGIQAGEPDPPEEPLTSQASVPPHQLRLGSLHPHTPYHIRVACTSSQGPSSWTHWLPVETPEGVPLGPPENISATRNGSQAFVHWQEPRAPLQGTLLGYRLAYQGQDTPEVLMDIGLRQEVTLELQGDGSVSNLTVCVAAYTAAGDGPWSLPVPLEAWRPGQAQPVHQLVKEPSTPAFSWPWWYVLLGAVVAAACVLILALFLVHRRKKETRYGEVFEPTVERGELVVRYRVRKSYSRRTTEATLNSLGISEELKEKLRDVMVDRHKVALGKTLGEGEFGAVMEGQLNQDDSILKVAVKTMKIAICTRSELEDFLSEAVCMKEFDHPNVMRLIGVCFQGSERESFPAPVVILPFMKHGDLHSFLLYSRLGDQPVYLPTQMLVKFMADIASGMEYLSTKRFIHRDLAARNCMLNENMSVCVADFGLSKKIYNGDYYRQGRIAKMPVKWIAIESLADRVYTSKSDVWSFGVTMWEIATRGQTPYPGVENSEIYDYLRQGNRLKQPADCLDGLYALMSRCWELNPQDRPSFTELREDLENTLKALPPAQEPDEILYVNMDEGGGYPEPPGAAGGADPPTQPDPKDSCSCLTAAEVHPAGRYVLCPSTTPSPAQPADRGSPAAPGQEDGA
Alternative Products
Event=Alternative splicing; Named isoforms=2; Name=Long; IsoId=P30530-1; Sequence=Displayed; Name=Short; IsoId=P30530-2; Sequence=VSP_005017
Alternative Sequence
429..437; Missing (in isoform Short)
3D Structural Models
Helix
109..111; 524..529; 533..535; 576..590; 628..637; 646..665; 675..677; 713..715; 718..723; 728..743; 755..763; 776..785; 790..792; 796..809
Beta Strand
37..39; 44..46; 52..63; 68..71; 80..87; 89..91; 94..106; 113..121; 124..127; 131..134; 140..143; 148..150; 156..159; 161..163; 165..167; 170..175; 178..187; 190..194; 201..209; 212..215; 219..223; 515..517; 536..544; 546..556; 558..571; 602..605; 616..621; 638..640; 678..680; 686..688; 698..700
3D Structure
X-ray crystallography (4)
Domain & Motif Annotations
Domain (FT)
27..128; Ig-like C2-type 1; 139..222; Ig-like C2-type 2; 227..331; Fibronectin type-III 1; 336..428; Fibronectin type-III 2; 536..807; Protein kinase
Region
26..92; Interaction with GAS6; 823..853; Disordered; 866..894; Disordered
Protein Families
- Protein kinase superfamily
- Tyr protein kinase family
- AXL/UFO subfamily
Sequence Similarities
Belongs to the protein kinase superfamily. Tyr protein kinase family. AXL/UFO subfamily.
Clinical Relevance
Disease Involvement
FDA approved drug targetsOncogeneProto-oncogene
Related Diseases
Biomarker
Approved; Phase 2; Phase 1/2; Investigative; Preclinical
Drug Targets
FDA approved drug targets
Drugs
SLC-391NULLVANDETANIBLDC1267GONIOTHALAMINXL999DUBERMATINIBBATIRAXCEPTBEMCENTINIBGLESATINIBBMS-777607SITRAVATINIBCEDIRANIBPF-562271BMS-754807CP-547632GROWTH ARREST SPECIFIC PROTEIN 6NINGETINIBCOMPOUND 19A [PMID: 30503936]COMPOUND 8I [PMID: 22765894]DOVITINIBRIPK1 INHIBITOR 22BGW843682XNVP-TAE684UNC4203CANLITINIBMERESTINIBGILTERITINIBADRIXETINIBBELIZATINIBENTRECTINIBBI-505ZANZALINTINIBCOMPOUND 6LI [CHAN ET AL., 2022]GILTERITINIB FUMARATESORAFENIBHESPERADINENAPOTAMAB VEDOTINDASATINIB ANHYDROUSILORASERTIBPROTEIN SBPI-9016LINIFANIBCENISERTIBONO-7475COMPOUND 1 [CRUZ-L&OACUTEPEZ ET AL., 2019]TOZASERTIBGEFITINIB
Interaction Protein
ENSG00000142627ENSG00000146648
Interaction Count
2
Interaction Dataset
intact_biogrid